Lacosamide as monotherapy in focal seizure: Literature review
Abstract Lacosamide is a newer approved antiepileptic drug (AED) characterized by its novel pharmacodynamic profile. It is now approved by United States Food and Drug Administration for use as monotherapy in adults (aged >17 years) with focal seizures based on historical controlled trial by Wechs...
Saved in:
| Published in | International journal of epilepsy Vol. 4; no. 1; pp. 55 - 58 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
A-12, Second Floor, Sector -2, NOIDA -201301, India
Elsevier India Pvt Ltd
01.06.2017
Thieme Medical and Scientific Publishers Private Ltd |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Abstract Lacosamide is a newer approved antiepileptic drug (AED) characterized by its novel pharmacodynamic profile. It is now approved by United States Food and Drug Administration for use as monotherapy in adults (aged >17 years) with focal seizures based on historical controlled trial by Wechsler RT et al in 2014. Randomized controlled trials on lacosamide monotherapy have demonstrated significant reduction in median seizure frequency. In addition, 50% responder rates for lacosamide was noted in half of the patients, with retention rate in two third of patients in 1 year follow up period. Adverse events reported in clinical trials were mostly mild to moderate in intensity. The most common adverse events were dizziness, headache, convulsion, nausea and fatigue while convulsion and dizziness were commonly responsible for drug discontinuation. Overall, lacosamide monotherapy can be a good treatment option in patients with focal seizure. |
|---|---|
| AbstractList | Abstract
Lacosamide is a newer approved antiepileptic drug (AED) characterized by its novel pharmacodynamic profile. It is now approved by United States Food and Drug Administration for use as monotherapy in adults (aged>17 years) with focal seizures based on historical controlled trial by Wechsler RT et al in 2014. Randomized controlled trials on lacosamide monotherapy have demonstrated significant reduction in median seizure frequency. In addition, 50% responder rates for lacosamide was noted in half of the patients, with retention rate in two third of patients in 1 year follow up period. Adverse events reported in clinical trials were mostly mild to moderate in intensity. The most common adverse events were dizziness, headache, convulsion, nausea and fatigue while convulsion and dizziness were commonly responsible for drug discontinuation. Overall, lacosamide monotherapy can be a good treatment option in patients with focal seizure. Abstract Lacosamide is a newer approved antiepileptic drug (AED) characterized by its novel pharmacodynamic profile. It is now approved by United States Food and Drug Administration for use as monotherapy in adults (aged >17 years) with focal seizures based on historical controlled trial by Wechsler RT et al in 2014. Randomized controlled trials on lacosamide monotherapy have demonstrated significant reduction in median seizure frequency. In addition, 50% responder rates for lacosamide was noted in half of the patients, with retention rate in two third of patients in 1 year follow up period. Adverse events reported in clinical trials were mostly mild to moderate in intensity. The most common adverse events were dizziness, headache, convulsion, nausea and fatigue while convulsion and dizziness were commonly responsible for drug discontinuation. Overall, lacosamide monotherapy can be a good treatment option in patients with focal seizure. Lacosamide is a newer approved antiepileptic drug (AED) characterized by its novel pharmacodynamic profile. It is now approved by United States Food and Drug Administration for use as monotherapy in adults (aged >17 years) with focal seizures based on historical controlled trial by Wechsler RT et al in 2014. Randomized controlled trials on lacosamide monotherapy have demonstrated significant reduction in median seizure frequency. In addition, 50% responder rates for lacosamide was noted in half of the patients, with retention rate in two third of patients in 1 year follow up period. Adverse events reported in clinical trials were mostly mild to moderate in intensity. The most common adverse events were dizziness, headache, convulsion, nausea and fatigue while convulsion and dizziness were commonly responsible for drug discontinuation. Overall, lacosamide monotherapy can be a good treatment option in patients with focal seizure. |
| Author | Barkate, Hanmant V. Sonkusare, Kishore R. |
| Author_xml | – sequence: 1 fullname: Sonkusare, Kishore R – sequence: 2 fullname: Barkate, Hanmant V |
| BookMark | eNp9kd9LwzAQx4NMcM79Az71H2i9JG3Wigoy_AUFH9TnkKZXlro2I-mU-debMlHwYU_3heNz3H3ulEx62yMh5xQSClRctIlpcZOwkBPKEgBxRKaMUR4LzovJb2ZwQubetwBAF0BTlk_Jdam09aozNUbKR53t7bBCpza7yPRRY7VaRx7N19bhZVSaIbSGkCOHHwY_z8hxo9Ye5z91Rt7u716Xj3H5_PC0vC1jzTMhYpUv9KIQtc5zmjUso7yulMgKhgwLBUqkTLNG0xRy4FUBFVMZVqoSOfKM65rPCNvP1c5677CRG2c65XaSghwdyFaODuToQFImg4MA0T00rAx2KFu7dX3Y8jBztWcwXBMudNJrg73G2jjUg6ytOYzf_MP12vQmSHzHHfq_DaQPgHwZHzP-hQoOkOacfwOGhIs0 |
| CitedBy_id | crossref_primary_10_1002_sscp_202000004 crossref_primary_10_1016_j_braindev_2020_04_009 |
| Cites_doi | 10.1111/epi.12934 10.1111/epi.12550 10.1016/j.seizure.2015.03.003 10.1007/s13311-011-0088-3 10.1046/j.1528-1157.44.s.1.5.x 10.1517/17425255.2014.883378 10.2165/00023210-200923070-00002 10.1111/j.1528-1167.2010.02522.x 10.1016/j.seizure.2015.04.003 10.1111/j.1755-5949.2012.00313.x 10.2147/TCRM.S5189 10.1016/j.nurt.2006.10.002 10.1586/14737175.9.1.33 10.1111/epi.12681 10.1111/j.1527-3458.2007.00001.x 10.1016/S0011-5029(03)00065-8 10.1016/j.eplepsyres.2012.03.007 10.1212/WNL.0000000000000119 10.1016/j.yebeh.2007.12.019 10.1007/s40265-015-0514-7 |
| ContentType | Journal Article |
| Copyright | Indian Epilepsy Society 2016 Indian Epilepsy Society |
| Copyright_xml | – notice: Indian Epilepsy Society – notice: 2016 Indian Epilepsy Society |
| DBID | 0U6 AAYXX CITATION |
| DOI | 10.1016/j.ijep.2016.12.006 |
| DatabaseName | Open Access: Thieme Open Access Journals CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | CrossRef |
| Database_xml | – sequence: 1 dbid: 0U6 name: Thieme (Open access) url: http://open.thieme.com sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2213-6339 |
| EndPage | 58 |
| ExternalDocumentID | 10_1016_j_ijep_2016_12_006 S2213632016300483 1_s2_0_S2213632016300483 |
| GroupedDBID | 0R 0U6 1 1~. 4.4 457 4G. 7-5 8P AAEDT AAIKJ AALRI AAOAW AAXLA AAXUO ABXDB ACGFS ADEZE AEKER AGHFR AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW BLXMC EBS EJD FDB FNPLU GBLVA H13 HZ M M41 MOBAO O9- OAUVE OK1 P-8 P-9 PC. Q38 ROL RTC SDF T5K --M .~1 0R~ 8P~ EFLBG HZ~ AAYXX AHRAW CITATION |
| ID | FETCH-LOGICAL-c3566-a87c796dc8815f2513dba6592e2e9a0a642c2fc140803b90b2a5ebab68e353cd3 |
| IEDL.DBID | .~1 |
| ISSN | 2213-6320 |
| IngestDate | Fri Aug 23 03:27:13 EDT 2024 Fri Aug 04 23:39:57 EDT 2023 Fri Feb 23 02:20:59 EST 2024 Thu Aug 18 17:23:03 EDT 2022 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Focal seizure Historical controlled trial Monotherapy Lacosamide |
| Language | English |
| License | CC BY-NC-ND 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3566-a87c796dc8815f2513dba6592e2e9a0a642c2fc140803b90b2a5ebab68e353cd3 |
| OpenAccessLink | http://dx.doi.org/10.1016/j.ijep.2016.12.006 |
| PageCount | 4 |
| ParticipantIDs | crossref_primary_10_1016_j_ijep_2016_12_006 thieme_journals_10_1016_j_ijep_2016_12_006 elsevier_sciencedirect_doi_10_1016_j_ijep_2016_12_006 elsevier_clinicalkeyesjournals_1_s2_0_S2213632016300483 |
| PublicationCentury | 2000 |
| PublicationDate | 20170600 |
| PublicationDateYYYYMMDD | 2017-06-01 |
| PublicationDate_xml | – month: 06 year: 2017 text: 20170600 |
| PublicationDecade | 2010 |
| PublicationPlace | A-12, Second Floor, Sector -2, NOIDA -201301, India |
| PublicationPlace_xml | – name: A-12, Second Floor, Sector -2, NOIDA -201301, India |
| PublicationTitle | International journal of epilepsy |
| PublicationYear | 2017 |
| Publisher | Elsevier India Pvt Ltd Thieme Medical and Scientific Publishers Private Ltd |
| Publisher_xml | – name: Elsevier India Pvt Ltd – name: Thieme Medical and Scientific Publishers Private Ltd |
| References | Durgin, Wade, Chen (bib0145) 2014 Lattanzi, Cagnetti, Foschi, Provinciali, Silvestrini (bib0125) 2015; 27 Beyreuther, Freitag, Heers, Krebsfänger, Scharfenecker, Stöhr (bib0070) 2007; 13 Topamax (topiramate). US prescribing information. Titusville, NJ: Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2013. [Internet]. [cited 2016 Mar 21]. Available from US FDA. Vimpat (lacosamide): highlights of prescribing information. [Internet]. [cited 2016 Mar 22]. Available from Berg, Berkovic, Brodie (bib0010) 2010; 51 Felbatol (felbamate). US prescribing information. Somerset, NJ: MEDA Pharmaceuticals Inc., 2012 [Internet]. [cited 2016 Mar 21]. Available from Bharucha (bib0020) 2003; 44 Fisher, Acevedo, Arzimanoglou (bib0005) 2014; 55 Kellinghaus (bib0100) 2009; 5 Ryvlin, Sperling, Chung (bib0135) 2014 Trileptal (oxcarbazepine). Summary of product characteristics. Camberley, Surrey, UK: Novartis Pharmaceuticals UK Ltd, 2013. [Internet]. [cited 2016 Mar 21]. Available from Doty, Rudd, Stoehr, Thomas (bib0090) 2007; 4 Wolff, Carrington, Varrin-Doyer (bib0105) 2012; 18 Beydoun, D’souza, Hebert, Lacosamide (bib0115) 2009; 9 Curia, Biagini, Perucca, Avoli (bib0085) 2009; 23 de Biase, Gigli, Valente, Merlino (bib0095) 2014; 10 Chung, Ceja, Gawłowicz (bib0055) 2012; 101 French, Kwan, Fakhoury (bib0060) 2014; 82 Wechsler, Li, French (bib0120) 2014; 55 de Boer, Mula, Sander (bib0015) 2008; 12 Lamictal (lamotrigine). Summary of product characteristics. Uxbridge, Middlesex, UK: GlaxoSmithKline UK, 2013. [Internet]. [cited 2016 Mar 21]. Available from . French, Temkin, Shneker (bib0050) 2012; 9 European Medicines Agency. Lacosamide: summary of product characteristics. [Internet]. [cited 2016 Mar 22]. Available from Stern, Sperling, Chung (bib0140) 2014 Shneker, Fountain (bib0025) 2003; 49 Sperling, Harvey, Grinnell, Cheng, Blum, the 045 Study Team (bib0065) 2015; 56 Scott (bib0110) 2015; 75 Giráldez, Toledano, García-Morales (bib0130) 2015; 29 Wolff (10.1016/j.ijep.2016.12.006_bib0105) 2012; 18 Giráldez (10.1016/j.ijep.2016.12.006_bib0130) 2015; 29 Scott (10.1016/j.ijep.2016.12.006_bib0110) 2015; 75 Berg (10.1016/j.ijep.2016.12.006_bib0010) 2010; 51 Kellinghaus (10.1016/j.ijep.2016.12.006_bib0100) 2009; 5 Ryvlin (10.1016/j.ijep.2016.12.006_bib0135) 2014 10.1016/j.ijep.2016.12.006_bib0035 Shneker (10.1016/j.ijep.2016.12.006_bib0025) 2003; 49 Lattanzi (10.1016/j.ijep.2016.12.006_bib0125) 2015; 27 10.1016/j.ijep.2016.12.006_bib0075 Curia (10.1016/j.ijep.2016.12.006_bib0085) 2009; 23 10.1016/j.ijep.2016.12.006_bib0030 Chung (10.1016/j.ijep.2016.12.006_bib0055) 2012; 101 Beyreuther (10.1016/j.ijep.2016.12.006_bib0070) 2007; 13 Stern (10.1016/j.ijep.2016.12.006_bib0140) 2014 Wechsler (10.1016/j.ijep.2016.12.006_bib0120) 2014; 55 de Biase (10.1016/j.ijep.2016.12.006_bib0095) 2014; 10 Fisher (10.1016/j.ijep.2016.12.006_bib0005) 2014; 55 Sperling (10.1016/j.ijep.2016.12.006_bib0065) 2015; 56 French (10.1016/j.ijep.2016.12.006_bib0060) 2014; 82 French (10.1016/j.ijep.2016.12.006_bib0050) 2012; 9 de Boer (10.1016/j.ijep.2016.12.006_bib0015) 2008; 12 10.1016/j.ijep.2016.12.006_bib0045 10.1016/j.ijep.2016.12.006_bib0040 Bharucha (10.1016/j.ijep.2016.12.006_bib0020) 2003; 44 10.1016/j.ijep.2016.12.006_bib0080 Beydoun (10.1016/j.ijep.2016.12.006_bib0115) 2009; 9 Durgin (10.1016/j.ijep.2016.12.006_bib0145) 2014 Doty (10.1016/j.ijep.2016.12.006_bib0090) 2007; 4 |
| References_xml | – volume: 23 start-page: 555 year: 2009 end-page: 568 ident: bib0085 article-title: Lacosamide publication-title: CNS Drugs contributor: fullname: Avoli – volume: 5 start-page: 757 year: 2009 end-page: 766 ident: bib0100 article-title: Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety publication-title: Ther Clin Risk Manag contributor: fullname: Kellinghaus – volume: 9 start-page: 176 year: 2012 end-page: 184 ident: bib0050 article-title: Conversion to monotherapy: first study using a historical control group publication-title: Neurotherapeutics contributor: fullname: Shneker – volume: 82 start-page: 590 year: 2014 end-page: 597 ident: bib0060 article-title: Pregabalin monotherapy in patients with partial-onset seizures: a historical-controlled trial publication-title: Neurology contributor: fullname: Fakhoury – volume: 55 start-page: 1088 year: 2014 end-page: 1098 ident: bib0120 article-title: Conversion to lacosamide monotherapy in the treatment of focal epilepsy: Results from a historical-controlled, multicenter, double-blind study publication-title: Epilepsia. contributor: fullname: French – volume: 56 start-page: 546 year: 2015 end-page: 555 ident: bib0065 article-title: Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America publication-title: Epilepsia contributor: fullname: the 045 Study Team – volume: 13 start-page: 21 year: 2007 end-page: 42 ident: bib0070 article-title: Lacosamide a review of preclinical properties publication-title: CNS Drug Rev contributor: fullname: Stöhr – volume: 44 start-page: 9 year: 2003 end-page: 11 ident: bib0020 article-title: Epidemiology of epilepsy in India publication-title: Epilepsia contributor: fullname: Bharucha – volume: 4 start-page: 145 year: 2007 end-page: 148 ident: bib0090 article-title: Lacosamide publication-title: Neurotherapeutics contributor: fullname: Thomas – volume: 51 start-page: 676 year: 2010 end-page: 685 ident: bib0010 article-title: Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005–2009 publication-title: Epilepsia contributor: fullname: Brodie – volume: 101 start-page: 92 year: 2012 end-page: 102 ident: bib0055 article-title: Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study publication-title: Epilepsy Res contributor: fullname: Gawłowicz – year: 2014 ident: bib0145 article-title: Lacosamide monotherapy treatment pathways in epilepsy patients in a US managed care population [abstract no 2.297] publication-title: 68th Annual Meeting of the American Epilepsy Society contributor: fullname: Chen – volume: 29 start-page: 119 year: 2015 end-page: 122 ident: bib0130 article-title: Long-term efficacy and safety of lacosamide monotherapy in the treatment of partial-onset seizures: a multicenter evaluation publication-title: Seizure contributor: fullname: García-Morales – volume: 27 start-page: 71 year: 2015 end-page: 74 ident: bib0125 article-title: Lacosamide monotherapy for partial onset seizures publication-title: Seizure contributor: fullname: Silvestrini – year: 2014 ident: bib0140 article-title: Focal seizure frequency by study phase and seizure type in conversion to lacosamide monotherapy study: a post hoc analysis [abstract no 3.291] publication-title: 68th Annual Meeting of the American Epilepsy Society contributor: fullname: Chung – volume: 10 start-page: 459 year: 2014 end-page: 468 ident: bib0095 article-title: Lacosamide for the treatment of epilepsy publication-title: Expert Opin Drug Metab Toxicol contributor: fullname: Merlino – volume: 18 start-page: 493 year: 2012 end-page: 500 ident: bib0105 article-title: Drug binding assays do not reveal specific binding of lacosamide to collapsin response mediator protein 2 (CRMP-2): no specific binding of lacosamide to CRMP-2 publication-title: CNS Neurosci Ther contributor: fullname: Varrin-Doyer – volume: 12 start-page: 540 year: 2008 end-page: 546 ident: bib0015 article-title: The global burden and stigma of epilepsy publication-title: Epilepsy Behav contributor: fullname: Sander – volume: 55 start-page: 475 year: 2014 end-page: 482 ident: bib0005 article-title: ILAE official report: a practical clinical definition of epilepsy publication-title: Epilepsia contributor: fullname: Arzimanoglou – volume: 49 start-page: 426 year: 2003 end-page: 478 ident: bib0025 publication-title: Epilepsy Dis Mon. contributor: fullname: Fountain – year: 2014 ident: bib0135 article-title: Conversion to lacosamide monotherapy: post hoc analysis on responder and seizure freedom rates [abstract no 3.292] publication-title: 68th Annual Meeting of the American Epilepsy Society contributor: fullname: Chung – volume: 75 start-page: 2143 year: 2015 end-page: 2154 ident: bib0110 article-title: Lacosamide a review in focal seizures in patients with epilepsy publication-title: Drugs contributor: fullname: Scott – volume: 9 start-page: 33 year: 2009 end-page: 42 ident: bib0115 article-title: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures publication-title: Expert Rev Neurother contributor: fullname: Lacosamide – ident: 10.1016/j.ijep.2016.12.006_bib0075 – volume: 56 start-page: 546 issue: April (4) year: 2015 ident: 10.1016/j.ijep.2016.12.006_bib0065 article-title: Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America publication-title: Epilepsia doi: 10.1111/epi.12934 contributor: fullname: Sperling – volume: 55 start-page: 475 issue: April (4) year: 2014 ident: 10.1016/j.ijep.2016.12.006_bib0005 article-title: ILAE official report: a practical clinical definition of epilepsy publication-title: Epilepsia doi: 10.1111/epi.12550 contributor: fullname: Fisher – volume: 27 start-page: 71 issue: April year: 2015 ident: 10.1016/j.ijep.2016.12.006_bib0125 article-title: Lacosamide monotherapy for partial onset seizures publication-title: Seizure doi: 10.1016/j.seizure.2015.03.003 contributor: fullname: Lattanzi – volume: 9 start-page: 176 issue: January (1) year: 2012 ident: 10.1016/j.ijep.2016.12.006_bib0050 article-title: Conversion to monotherapy: first study using a historical control group publication-title: Neurotherapeutics doi: 10.1007/s13311-011-0088-3 contributor: fullname: French – year: 2014 ident: 10.1016/j.ijep.2016.12.006_bib0140 article-title: Focal seizure frequency by study phase and seizure type in conversion to lacosamide monotherapy study: a post hoc analysis [abstract no 3.291] publication-title: 68th Annual Meeting of the American Epilepsy Society contributor: fullname: Stern – volume: 44 start-page: 9 issue: s1 year: 2003 ident: 10.1016/j.ijep.2016.12.006_bib0020 article-title: Epidemiology of epilepsy in India publication-title: Epilepsia doi: 10.1046/j.1528-1157.44.s.1.5.x contributor: fullname: Bharucha – ident: 10.1016/j.ijep.2016.12.006_bib0030 – volume: 10 start-page: 459 issue: March (3) year: 2014 ident: 10.1016/j.ijep.2016.12.006_bib0095 article-title: Lacosamide for the treatment of epilepsy publication-title: Expert Opin Drug Metab Toxicol doi: 10.1517/17425255.2014.883378 contributor: fullname: de Biase – volume: 23 start-page: 555 issue: 7 year: 2009 ident: 10.1016/j.ijep.2016.12.006_bib0085 article-title: Lacosamide publication-title: CNS Drugs doi: 10.2165/00023210-200923070-00002 contributor: fullname: Curia – ident: 10.1016/j.ijep.2016.12.006_bib0045 – ident: 10.1016/j.ijep.2016.12.006_bib0080 – volume: 51 start-page: 676 issue: April (4) year: 2010 ident: 10.1016/j.ijep.2016.12.006_bib0010 article-title: Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005–2009 publication-title: Epilepsia doi: 10.1111/j.1528-1167.2010.02522.x contributor: fullname: Berg – volume: 29 start-page: 119 issue: July year: 2015 ident: 10.1016/j.ijep.2016.12.006_bib0130 article-title: Long-term efficacy and safety of lacosamide monotherapy in the treatment of partial-onset seizures: a multicenter evaluation publication-title: Seizure doi: 10.1016/j.seizure.2015.04.003 contributor: fullname: Giráldez – volume: 18 start-page: 493 issue: June (6) year: 2012 ident: 10.1016/j.ijep.2016.12.006_bib0105 article-title: Drug binding assays do not reveal specific binding of lacosamide to collapsin response mediator protein 2 (CRMP-2): no specific binding of lacosamide to CRMP-2 publication-title: CNS Neurosci Ther doi: 10.1111/j.1755-5949.2012.00313.x contributor: fullname: Wolff – volume: 5 start-page: 757 year: 2009 ident: 10.1016/j.ijep.2016.12.006_bib0100 article-title: Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety publication-title: Ther Clin Risk Manag doi: 10.2147/TCRM.S5189 contributor: fullname: Kellinghaus – volume: 4 start-page: 145 issue: 1 year: 2007 ident: 10.1016/j.ijep.2016.12.006_bib0090 article-title: Lacosamide publication-title: Neurotherapeutics doi: 10.1016/j.nurt.2006.10.002 contributor: fullname: Doty – volume: 9 start-page: 33 issue: January (1) year: 2009 ident: 10.1016/j.ijep.2016.12.006_bib0115 article-title: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures publication-title: Expert Rev Neurother doi: 10.1586/14737175.9.1.33 contributor: fullname: Beydoun – volume: 55 start-page: 1088 issue: July (7) year: 2014 ident: 10.1016/j.ijep.2016.12.006_bib0120 article-title: Conversion to lacosamide monotherapy in the treatment of focal epilepsy: Results from a historical-controlled, multicenter, double-blind study publication-title: Epilepsia. doi: 10.1111/epi.12681 contributor: fullname: Wechsler – volume: 13 start-page: 21 issue: 1 year: 2007 ident: 10.1016/j.ijep.2016.12.006_bib0070 article-title: Lacosamide a review of preclinical properties publication-title: CNS Drug Rev doi: 10.1111/j.1527-3458.2007.00001.x contributor: fullname: Beyreuther – volume: 49 start-page: 426 issue: July (7) year: 2003 ident: 10.1016/j.ijep.2016.12.006_bib0025 publication-title: Epilepsy Dis Mon. doi: 10.1016/S0011-5029(03)00065-8 contributor: fullname: Shneker – volume: 101 start-page: 92 issue: August (1–2) year: 2012 ident: 10.1016/j.ijep.2016.12.006_bib0055 article-title: Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study publication-title: Epilepsy Res doi: 10.1016/j.eplepsyres.2012.03.007 contributor: fullname: Chung – year: 2014 ident: 10.1016/j.ijep.2016.12.006_bib0145 article-title: Lacosamide monotherapy treatment pathways in epilepsy patients in a US managed care population [abstract no 2.297] publication-title: 68th Annual Meeting of the American Epilepsy Society contributor: fullname: Durgin – ident: 10.1016/j.ijep.2016.12.006_bib0035 – volume: 82 start-page: 590 issue: February (7) year: 2014 ident: 10.1016/j.ijep.2016.12.006_bib0060 article-title: Pregabalin monotherapy in patients with partial-onset seizures: a historical-controlled trial publication-title: Neurology doi: 10.1212/WNL.0000000000000119 contributor: fullname: French – volume: 12 start-page: 540 issue: May (4) year: 2008 ident: 10.1016/j.ijep.2016.12.006_bib0015 article-title: The global burden and stigma of epilepsy publication-title: Epilepsy Behav doi: 10.1016/j.yebeh.2007.12.019 contributor: fullname: de Boer – ident: 10.1016/j.ijep.2016.12.006_bib0040 – year: 2014 ident: 10.1016/j.ijep.2016.12.006_bib0135 article-title: Conversion to lacosamide monotherapy: post hoc analysis on responder and seizure freedom rates [abstract no 3.292] publication-title: 68th Annual Meeting of the American Epilepsy Society contributor: fullname: Ryvlin – volume: 75 start-page: 2143 issue: December (18) year: 2015 ident: 10.1016/j.ijep.2016.12.006_bib0110 article-title: Lacosamide a review in focal seizures in patients with epilepsy publication-title: Drugs doi: 10.1007/s40265-015-0514-7 contributor: fullname: Scott |
| SSID | ssj0001701428 |
| Score | 2.0519118 |
| SecondaryResourceType | review_article |
| Snippet | Abstract Lacosamide is a newer approved antiepileptic drug (AED) characterized by its novel pharmacodynamic profile. It is now approved by United States Food... Lacosamide is a newer approved antiepileptic drug (AED) characterized by its novel pharmacodynamic profile. It is now approved by United States Food and Drug... Abstract Lacosamide is a newer approved antiepileptic drug (AED) characterized by its novel pharmacodynamic profile. It is now approved by United States Food... |
| SourceID | crossref thieme elsevier |
| SourceType | Aggregation Database Publisher |
| StartPage | 55 |
| SubjectTerms | Focal seizure Historical controlled trial Lacosamide Monotherapy Neurology Review article |
| SummonAdditionalLinks | – databaseName: Open Access: Thieme Open Access Journals dbid: 0U6 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LSwMxEA6lXryIomJ9kYMndWHz2N2s4EHEUqR60UJvIcnO4hZapdse9Nc72UfrwQreZzcwM8k3M5n5QsiFNNKZyJlAYfYQyDyDIE1sGvAc0Vu40Cjup5GfnuPBSD6Oo3GHXG-4wa86sYoJeGZJFleFO8-vvcUR5nwDVziK1xWVJPT0Yf41Oc5EEAseNlMyv_9mIxIt3gqYwg-Y6e-SnSY-pHe1QfdIB2b75HaI51ZppkUG1JQUPaeZm_qkxYzmHo5oCcXXcg43dLgiSqb1XMoBGfUfXu8HQfPuQeAERleBUYlL0jhzSrEoxwBEZNb460_gkJrQYMrgeO4wNVKhsGlouYnAGhsrEJFwmTgk3dn7DI4IzRPr2WMYwjBICSxNLW5haSyGhUxa2SNXrQ70R01vodu-r4n2GtNeY5pxjRrrkaRVk24HN_GogbLx-1IzXaKkfvEW8AZgFaOXEj0Srb5soL2GbI3m_nPFy9oaer3ERuHj_wifkG3uEboqqJyS7mK-hDOMLxb2vHKrb0CpxuY priority: 102 providerName: Thieme |
| Title | Lacosamide as monotherapy in focal seizure: Literature review |
| URI | https://www.clinicalkey.es/playcontent/1-s2.0-S2213632016300483 https://dx.doi.org/10.1016/j.ijep.2016.12.006 http://dx.doi.org/10.1016/j.ijep.2016.12.006 |
| Volume | 4 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEA6lJy-iqFhf5OBJWbt57EvwIMVSpHrRQm8hyc7iFlpLtz3owd_uZB-tInrwsodlwiwzyXyTbOYbQs6lllYHVnsx7h48maXgJZFJPJ4hegvr65i7auSHx3AwkvfjYNwivaYWxl2rrGN_FdPLaF2_6dbW7M7zvPvEOROhQAArWaNix_gpEYxwTl99sM05S-Q7UjHXYw7lPTegrp2prnnlE3C0lSwsTwVd46Nf8Gn5ksMUvoBPf4ds11kjva0-bJe0YLZHboYYzQo9zVOguqA4n-pqqjeaz2jmQIoWkL-vFnBNh2v6ZFpVq-yTUf_uuTfw6m4InhWYc3k6jmyUhKmNYxZkmJaI1Gj3UxQ4JNrXuJGwPLO4YYp9YRLfcB2A0SaMQQTCpuKAtGevMzgkNIuM45RhCM4gJbAkMbiwpTaYLDJpZIdcNjZQ84r0QjW3wSbKWUw5iynGFVqsQ6LGTKop58QABEW9GgrFVIGS6ofHOiRYj_zmdIXx_E-NF5U31EbFr8JH_1RyTLa4g_DyxOWEtJeLFZxiArI0Z-UMw6c_Cj8B5cTWWg |
| link.rule.ids | 315,786,790,4521,20918,27957,27958,45620,54938,54966 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEA5aD3oRRcX6zMGTsnbz2JfgQYqlautFBW8hyc7iFlqLWw968Lc72YcPRA9el4QJM8l8M7PzIORAaml1YLUXo_fgySwFL4lM4vEM0VtYX8fcVSMPr8P-nby8D-7nSLephXFplbXur3R6qa3rL52am51pnnduOGciFAhgZdeoWMyTBWfOu_kNx2_sM9AS-a6rmBsyhxs8t6MunqnyvPIRuL6VLCzDgm7y0S8ANXvIYQxf0Ke3QpZrs5GeVSdbJXMwWSOnA1RnhR7nKVBdULxQdTnVC80nNHMoRQvIX5-f4IQOPvon06pcZZ3c9c5vu32vHofgWYFGl6fjyEZJmNo4ZkGGdolIjXZ_RYFDon2NnoTlmUWPKfaFSXzDdQBGmzAGEQibig3SmjxOYJPQLDKuqQxDdAYpgSWJwZcttUFrkUkj2-So4YGaVl0vVJMONlKOY8pxTDGukGNtEjVsUk09J2ogKOrnUCimClypfoisTYKPnd-krlCh_0nxsJKG-iTx6-KtfxLZJ4v92-FADS6ur7bJEnd4XoZfdkhr9vQMu2iNzMxeedveAa5s2J4 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEA66gngRRcX1mYMnJW7z6EvwIOqy6iqCLngLSTrFCq6LXQ_6651sW9eDCp47bcpMOt_MdOYLIXvKKGdCZ1iC2QNTeQYsjW3KRI7oLV1gEuGnka9vot5AXT6ED_VkXVm3VY4fC3gG5nynhxv7VotRxX5adqDWcNkZZXln2qxVPIEnn-TRpLYXRId4eZbMYfIjfZ9XMIimhZc48Cxj_tA5wSWLpAjqYZqfH_UrYFWv-Q2NuktksQ4j6Ull92UyA8MVctxH91aa5yIDakqKG6wer3qnxZDmHrVoCcXH2ysc0f4XnzKtxldWyaB7fn_aY_XxCMxJDMKYSWIXp1HmkoSHOcYpMrPG_yUFAakJDGYWTuQOM6gkkDYNrDAhWGOjBGQoXSbXSGv4MoR1QvPYepIZjmgNSgFPU4tfujIWo0eurGqTg0YHelSxYOimPexJe41przHNhUaNtUncqEk3853okaBsjKe5LlFS33kLeAPwCfFXItsk_LqzjgAqZNfo4P9ccb-yhp4u8avwxn-Ed8n87VlX9y9urjbJgvCYPinBbJHW-PUNtjEiGdudyQ77BFql2O4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lacosamide+as+monotherapy+in+focal+seizure%3A+Literature+review&rft.jtitle=International+journal+of+epilepsy&rft.au=Sonkusare%2C+Kishore+R&rft.au=Barkate%2C+Hanmant+V&rft.date=2017-06-01&rft.issn=2213-6320&rft.eissn=2213-6339&rft.volume=4&rft.issue=1&rft.spage=55&rft.epage=58&rft_id=info:doi/10.1016%2Fj.ijep.2016.12.006&rft.externalDocID=1_s2_0_S2213632016300483 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F22136320%2FS2213632017X0002X%2Fcov150h.gif |